Video Shorts
0:58
What Were the Biggest News at the 2026 ASCO Annual Meeting?
5 months ago
by
Joaquim Bellmunt, MD, PhD
0:48
Highlighting the Potential Role of Emi-Le in Aggressive ACC Management
5 months ago
by
Glenn J. Hanna, MD
0:37
Examining the Role of Robotics in Prostate Cancer
5 months ago
by
David Chen, MD
1:05
Potential Applications for Tumor-Informed ctDNA Deep Sequencing in Osteosarcoma
5 months ago
by
R. Lor Randall, MD, FACS
0:39
The Evaluation of HER3-DXd in Breast Cancer
5 months ago
by
Virginia G. Kaklamani, MD, DSc
1:10
What to Know About Toxicity Management With Zanidatamab Regimens From HERIZON-GEA-01
5 months ago
by
Geoffrey Y. Ku, MD
1:27
Examining Subgroup Data From PSMAaddition in mHSPC
5 months ago
by
Fred Saad, CQ, MD, FRCS, FCAHS
1:27
What Were the Most Notable News in Bladder Cancer at AUA 2026?
5 months ago
by
Mark D. Tyson, II, MD, MPH
0:32
Unpacking Patient Reported Outcome Data From IMvigor011 in Bladder Cancer
5 months ago
by
Joaquim Bellmunt, MD, PhD
1:10
HERIZON-GEA-01 Subgroup Analysis Supports Broad Benefit With Zanidatamab Regimen
5 months ago
by
Geoffrey Y. Ku, MD
2:32
MonumenTAL-3 Leads Key Myeloma Data Set To Emerge at EHA 2026
5 months ago
by
Rahul Banerjee, MD
0:55
What Were Some of the Notable Takeaways From the 2026 ASCO Annual Meeting?
5 months ago
by
Ravi B. Parikh, MD, MPP, FACP
1:53
Highlighting Brain Cancer Radiation Strategies and Needs for World Brain Tumor Day
5 months ago
by
Raj Singh, MD
1:30
Daraxonrasib Represents a Major Breakthrough for Pancreatic Cancer Care
5 months ago
by
Tanios S. Bekaii-Saab, MD
1:11
Unpacking the NEXUS-01 Data in Bladder Cancer
5 months ago
by
Gopa Iyer, MD
1:00
RASolute 302 Read Out Marks An Exciting New Chapter in Pancreatic Cancer Care
5 months ago
by
Vincent J. Picozzi, MD
0:50
Aglatimagene Besadenovec Emerges in Prostate Cancer
5 months ago
by
Mark Garzotto, MD
1:07
Giants of Cancer Care 2026
5 months ago
by
Jonathan Lee, MD, MSc(+1 more)
3:51
Recapping the ASCO 2026 OncLive Fellows Forum: Lung Cancer
5 months ago
by
Chinmay Jani, MD
1:30
The “Million-Dollar Question”: Can Romiplostim Improve Outcomes by Maintaining Chemo Dose Intensity?
5 months ago
by
Gerald Soff, MD
0:36
An Analysis of Urinary Proteomics in Bladder Cancer
5 months ago
by
Mark Farha, MD
0:50
Investigating TTFields in Newly Diagnosed Glioblastoma
5 months ago
by
David Tran, MD, PhD
0:39
How Is AI Changing GU Cancer Surgery?
5 months ago
by
David Chen, MD
1:06
Inside the Science Behind Personalized Vaccine Development for Pancreatic Cancer
5 months ago
by
Paul E. Oberstein, MD
1:04
Previewing Updated Data From ASCENT-03 and ASCENT-04 Upcoming at ASCO 2026
5 months ago
by
Jane L. Meisel, MD
1:08
Raising Bladder Cancer Awareness
5 months ago
by
Ashish M. Kamat, MD
1:41
Previewing ASCO 2026: SUCCESSOR-2 Trial in R/R Multiple Myeloma
5 months ago
by
Rahul Banerjee, MD
3:58
OncLive News Roundup for the Week of 5/17
5 months ago
by
Chris Ryan
1:48
Previewing Key Breast Cancer Abstracts to Watch at ASCO 2026
5 months ago
by
Kevin Kalinsky, MD, MS
1:05
Breaking Down Mogamulizumab-Associated Rashes in CTCL
5 months ago
by
Stefan K. Barta, MD, MS
Advertisement
Advertisement
Trending on OncLive
1
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ESMO 2026
2
TP53 Comutations, Long-Term Toxicity, and Sunvozertinib Access Shape EGFR+ NSCLC Treatment Decisions
3
Phase 1 Study of BGB-B2033 (GPC3 x 4-1BB Bispecific Antibody) Monotherapy: First Disclosure of Dose Optimization and Dose Escalation Update in Advanced Hepatocellular Carcinoma
4
Outpatient Models and Prophylactic Measures Help Bring Bispecifics Into Community Practice for R/R Myeloma
5